Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

Targeting mitochondrial metabolism as a novel therapeutic strategy for treatment ...

Diffuse midline glioma (DMG) is a highly aggressive pediatric brain tumor with a dismal prognosis. A major treatment barrier is tumor hypoxia—low oxygen levels that reduce the effectiveness of radiotherapy and chemotherapy. Our recent research found that targeting mitochondrial metabolism, specifically by reducing oxygen consumption in tumor cells, ...

Beyond BRAF and MEK inhibition: Evaluation of alternative therapeutic strategies ...

Diffuse Midline Gliomas (DMG), including Diffuse Intrinsic Pontine Gliomas (DIPG), are extremely difficult to treat, and no curative therapies are currently available. Children diagnosed with these tumors typically survive only 11 to 13 months. One major contributor to this poor prognosis is the presence of the H3K27M mutation. It has ...

Multiomic Characterization of Central Nervous System Tumors using whole methylome ...

Brain tumors are the most common type of solid cancer and the leading cause of cancer-related deaths in children. Recent updates in how these tumors are classified now focus more on genetic testing to unravel the underlying molecular biology, which can change how doctors assess risk, predict outcomes, and provide ...

Identifying novel treatment combinations targeting ERK signaling dependence in pediatric ...

High-grade gliomas (HGG) are aggressive brain tumors that are a leading cause of cancer death in children and young adults. Some HGGs have specific changes in their DNA (like BRAF or NF1 mutations) that affect a pathway called RAS-ERK, which controls how cells grow and repair damage. While drugs that ...

Exploiting nucleolar vulnerabilities in paediatric high-grade gliomas

Aggressive brain cancers such as paediatric high-grade gliomas H3.3 and ATRX mutations are among the most challenging to treat, with limited options and poor outcomes. Recent discoveries, however, are opening promising new paths for targeted therapy. Our research shows that mutations in key chromatin regulators—H3.3 and ATRX—...

Targeting the Tumor Immune Microenvironment in H3.1K27M Diffuse ...

Diffuse midline gliomas (DMGs) are highly aggressive pediatric brain tumors with limited treatment options. Most are driven by mutations in two versions of histone H3, mainly H3.3K27M (about 80% of cases) and H3.1K27M (about 20%). Despite affecting the same amino acid, they lead to different disease behaviors and ...